PharmaResearch Receives FDA Clearance for Phase 1 Trial of Nano Anticancer Drug PRD-101
核心洞察
PharmaResearch Co., Ltd. (搜索) received U.S. FDA clearance for its Investigational New Drug application for PRD-101 (搜索), enabling initiation of a Phase 1 clinical trial in the United States.
PRD-101 (搜索) is a next-generation nano anticancer drug candidate formulated using nucleotide fragments produced through the company's proprietary DOT® (DNA (搜索) Optimizing Technology).
The Phase 1 trial will be conducted across up to seven clinical sites in the United States and is expected to enroll approximately 90 patients with locally advanced or metastatic solid tumors.
PharmaResearch Co., Ltd. (搜索) announced on February 6, 2026, that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for PRD-101 (搜索), a next-generation nano anticancer drug candidate. The FDA clearance enables the South Korean biopharmaceutical company to initiate a Phase 1 clinical trial in the United States.
Novel Nanotechnology Platform
PRD-101 (搜索) is formulated using nucleotide fragments produced through PharmaResearch's proprietary DOT® (DNA (搜索) Optimizing Technology). The drug leverages the company's nucleotide-based Advanced DOT™ drug delivery platform, which is designed to enable efficient loading of therapeutics and improve pharmacokinetics.
The development of PRD-101 (搜索) represents collaborative efforts between PharmaResearch and University of California Irvine researchers, along with support from organizations like the U.S. NCL. PharmaResearch holds patents and exclusive licenses associated with PRD-101, marking a milestone in the company's innovative endeavors.
Phase 1 Trial Design
The Phase 1 clinical trial will be conducted across up to seven clinical sites in the United States and is expected to enroll approximately 90 patients with locally advanced or metastatic solid tumors. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of PRD-101 (搜索).
"The FDA clearance of our IND application marks an important milestone for PRD-101 (搜索). Through this Phase 1 trial, we aim to further characterize PRD-101 and continue advancing our oncology pipeline," PharmaResearch stated.
Addressing Treatment Limitations
Traditional anticancer drugs often face limitations due to high toxicity, which restricts patient eligibility and necessitates careful dosage management. PharmaResearch anticipates that PRD-101 (搜索) will address these unmet medical needs in anticancer therapy.
The company's approach utilizes nucleotide fragments produced through its proprietary DNA (搜索) optimizing technology in nanoparticle anticancer formulations, representing what the company describes as a significant advancement in cancer treatment.
Company Background
PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life through regenerative medicine. With a diverse portfolio that includes medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients—DOT® PDRN and DOT® PN—which are protected by a suite of patents. The company is headquartered in Gangneung-si, Gangwon-do, South Korea, and also has a subsidiary in Costa Mesa, California.